Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response

Journal of Immunology

Volumn 193, Issue 2, 2014, Pages 735-745

  Zhao, Lixiang ^a   Mei, Yu ^a   Sun, Qing ^b   Guo, Linghua ^a   Wu, Yan ^a   Yu, Xiao ^a   Hu, Bo ^a   Liu, Xiufan ^b   Liu, Haiyan ^a  

^a SOOCHOW UNIVERSITY   (China)

^b YANGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLOGOUS TUMOR VACCINE; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE INSERTION; GENE PRODUCT; GENETIC STABILITY; IL 7 GENE; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR IMMUNITY; TUMOR MODEL; UPREGULATION; VACCINE PRODUCTION; VIRAL GENETICS; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DNA, RECOMBINANT; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-7; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEWCASTLE DISEASE VIRUS;

EID: 84904245024     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400004     Document Type: Article

References (50)

1. Csatary, L. K. 1971. Viruses in the treatment of cancer. Lancet 2: 825.
2. Lorence, R. M., B. B. Katubig, K. W. Reichard, H. M. Reyes, A. Phuangsab, M. D. Sassetti, R. J. Walter, and M. E. Peeples. 1994. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 54: 6017-6021.
3. Lorence, R. M., K. W. Reichard, B. B. Katubig, H. M. Reyes, A. Phuangsab, B. R. Mitchell, C. J. Cascino, R. J. Walter, and M. E. Peeples. 1994. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J. Natl. Cancer Inst. 86: 1228-1233.
4. Lorence, R. M., P. A. Rood, and K. W. Kelley. 1988. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-a and augmentation of its cytotoxicity. J. Natl. Cancer Inst. 80: 1305-1312.
5. Phuangsab, A., R. M. Lorence, K. W. Reichard, M. E. Peeples, and R. J. Walter. 2001. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 172: 27-36.
6. Reichard, K. W., R. M. Lorence, C. J. Cascino, M. E. Peeples, R. J. Walter, M. B. Fernando, H. M. Reyes, and J. A. Greager. 1992. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 52: 448-453.
7. Sinkovics, J. G., and J. C. Horvath. 2000. Newcastle disease virus (NDV): brief history of its oncolytic strains. J. Clin. Virol. 16: 1-15.
8. Nelson, N. J. 1999. Scientific interest in Newcastle disease virus is reviving. J. Natl. Cancer Inst. 91: 1708-1710.
9. Clemens, M. J., and A. Elia. 1997. The double-stranded RNA-dependent protein kinase PKR: structure and function. J. Interferon Cytokine Res. 17: 503-524.
10. Kato, H., S. Sato, M. Yoneyama, M. Yamamoto, S. Uematsu, K. Matsui, T. Tsujimura, K. Takeda, T. Fujita, O. Takeuchi, and S. Akira. 2005. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23: 19-28.
11. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4: 499-511.
12. Janke, M., B. Peeters, O. de Leeuw, R. Moorman, A. Arnold, P. Fournier, and V. Schirrmacher. 2007. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther. 14: 1639-1649.
13. Batliwalla, F. M., B. A. Bateman, D. Serrano, D. Murray, S. Macphail, V. C. Maino, J. C. Ansel, P. K. Gregersen, and C. A. Armstrong. 1998. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol. Med. 4: 783-794.
14. Zorn, U., S. Duensing, F. Langkopf, G. Anastassiou, H. Kirchner, M. Hadam, J. Knüver-Hopf, and J. Atzpodien. 1997. Active specific immunotherapy of renalcell carcinoma: cellular and humoral immune responses. Cancer Biother. Radiopharm. 12: 157-165.
15. Liang, W., H. Wang, T. M. Sun, W. Q. Yao, L. L. Chen, Y. Jin, C. L. Li, and F. J. Meng. 2003. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J. Gastroenterol. 9: 495-498.
16. Ockert, D., V. Schirrmacher, N. Beck, E. Stoelben, T. Ahlert, J. Flechtenmacher, E. Hagmüller, R. Buchcik, M. Nagel, and H. D. Saeger. 1996. Newcastle diseasevirus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin. Cancer Res. 2: 21-28.
17. Freeman, A. I., Z. Zakay-Rones, J. M. Gomori, E. Linetsky, L. Rasooly, E. Greenbaum, S. Rozenman-Yair, A. Panet, E. Libson, C. S. Irving, et al. 2006. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13: 221-228.
18. Pecora, A. L., N. Rizvi, G. I. Cohen, N. J. Meropol, D. Sterman, J. L. Marshall, S. Goldberg, P. Gross, J. D. O'Neil, W. S. Groene, et al. 2002. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20: 2251-2266.
19. Schirrmacher, V., C. Haas, R. Bonifer, T. Ahlert, R. Gerhards, and C. Ertel. 1999. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 6: 63-73.
20. Schirrmacher, V., C. Haas, R. Bonifer, and C. Ertel. 1997. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. Clin. Cancer Res. 3: 1135-1148.
21. Heicappell, R., V. Schirrmacher, P. von Hoegen, T. Ahlert, and B. Appelhans. 1986. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int. J. Cancer 37: 569-577.
22. Schirrmacher, V., and R. Heicappell. 1987. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity. Clin. Exp. Metastasis 5: 147-156.
23. Steiner, H. H., M. M. Bonsanto, P. Beckhove, M. Brysch, K. Geletneky, R. Ahmadi, R. Schuele-Freyer, P. Kremer, G. Ranaie, D. Matejic, et al. 2004. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol. 22: 4272-4281.
24. Karcher, J., G. Dyckhoff, P. Beckhove, C. Reisser, M. Brysch, Y. Ziouta, B. H. Helmke, H. Weidauer, V. Schirrmacher, and C. Herold-Mende. 2004. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 64: 8057-8061.
25. Peeters, B. P., O. S. de Leeuw, G. Koch, and A. L. Gielkens. 1999. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol. 73: 5001-5009.
26. Niu, N., and X. Qin. 2013. New insights into IL-7 signaling pathways during early and late T cell development. Cell. Mol. Immunol. 10: 187-189.
27. Bradley, L. M., L. Haynes, and S. L. Swain. 2005. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol. 26: 172-176.
28. Martin, C. E., E. M. van Leeuwen, S. J. Im, D. C. Roopenian, Y. C. Sung, and C. D. Surh. 2013. IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R. Blood 121: 4484-4492.
29. Koenen, P., S. Heinzel, E. M. Carrington, L. Happo, W. S. Alexander, J. G. Zhang, M. J. Herold, C. L. Scott, A. M. Lew, A. Strasser, and P. D. Hodgkin. 2013. Mutually exclusive regulation of T cell survival by IL-7R and antigen receptor-induced signals. Nat. Commun. 4: 1735.
30. Sun, Q., L. Zhao, Q. Song, Z. Wang, X. Qiu, W. Zhang, M. Zhao, G. Zhao, W. Liu, H. Liu, et al. 2012. Hybrid- and complex-type N-glycans are not essential for Newcastle disease virus infection and fusion of host cells. Glycobiology 22: 369-378.
31. Liu, Y. L., S. L. Hu, Y. M. Zhang, S. J. Sun, A. Romer-Oberdorfer, J. Veits, Y. T. Wu, H. Q. Wan, and X. F. Liu. 2007. Generation of a velogenic Newcastle disease virus from cDNA and expression of the green fluorescent protein. Arch. Virol. 152: 1241-1249.
32. Pang, Y. L., H. G. Zhang, J. R. Peng, X. W. Pang, S. Yu, Q. Xing, X. Yu, L. Gong, Y. H. Yin, Y. Zhang, and W. F. Chen. 2009. The immunosuppressive tumor microenvironment in hepatocellular carcinoma. Cancer Immunol. Immunother. 58: 877-886.
33. Schirrmacher, V. 2005. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol. Immunother. 54: 587-598.
34. Zhao, L., and H. Liu. 2012. Newcastle disease virus: a promising agent for tumour immunotherapy. Clin. Exp. Pharmacol. Physiol. 39: 725-730.
35. Shobana, R., S. K. Samal, and S. Elankumaran. 2013. Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy. J. Virol. 87: 3792-3800.
36. Silberhumer, G. R., P. Brader, J. Wong, I. S. Serganova, M. Gönen, S. J. Gonzalez, R. Blasberg, D. Zamarin, and Y. Fong. 2010. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol. Cancer Ther. 9: 2761-2769.
37. Vigil, A., M. S. Park, O. Martinez, M. A. Chua, S. Xiao, J. F. Cros, L. Martínez- Sobrido, S. L.Woo, and A. García-Sastre. 2007. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 67: 8285-8292.
38. Wei, D., N. Sun, G. Nan, Y. Wang, H. Q. Liu, B. Peeters, Z. N. Chen, and H. Bian. 2012. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Hum. Gene Ther. 23: 700-710.
39. Mackall, C. L., T. J. Fry, and R. E. Gress. 2011. Harnessing the biology of IL-7 for therapeutic application. Nat. Rev. Immunol. 11: 330-342.
40. Pellegrini, M., T. Calzascia, J. G. Toe, S. P. Preston, A. E. Lin, A. R. Elford, A. Shahinian, P. A. Lang, K. S. Lang, M. Morre, et al. 2011. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 144: 601-613.
41. Plumb, A. W., D. T. Patton, J. H. Seo, E. K. Loveday, F. Jean, S. F. Ziegler, and N. Abraham. 2012. Interleukin-7, but not thymic stromal lymphopoietin, plays a key role in the T cell response to influenza A virus. PLoS ONE 7: e50199.
42. Toe, J. G., M. Pellegrini, and T. W. Mak. 2013. Promoting immunity during chronic infection - the therapeutic potential of common g-chain cytokines. Mol. Immunol. 56: 38-47.
43. Schroten-Loef, C., C. M. de Ridder, S. Reneman, M. Crezee, A. Dalgleish, S. M. Todryk, C. H. Bangma, and R. Kraaij. 2009. A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy. Cancer Immunol. Immunother. 58: 373-381.
44. Schroten, C., R. Scheffer, L. Boon, C. M. de Ridder, C. H. Bangma, and R. Kraaij. 2012. Tumor protection by IL-7 secreting whole cell vaccine is merely mediated by NK1.1-positive cells. J. Immunother. 35: 125-130.
45. McBride, W. H., J. D. Thacker, S. Comora, J. S. Economou, D. Kelley, D. Hogge, S. M. Dubinett, and G. J. Dougherty. 1992. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res. 52: 3931-3937.
46. Miller, A. R., W. H. McBride, S. M. Dubinett, G. J. Dougherty, J. D. Thacker, H. Shau, D. B. Kohn, R. C. Moen, M. J. Walker, R. Chiu, et al. 1993. Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunologic properties with interleukin-2. Blood 82: 3686-3694.
47. Sharma, S., P. W. Miller, M. Stolina, L. Zhu, M. Huang, R. W. Paul, and S. M. Dubinett. 1997. Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/ herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther. 4: 1361-1370.
48. Eisenberg, G., R. Uzana, A. Pato, S. Frankenburg, S. Merims, E. Yefenof, S. Ferrone, T. Peretz, A. Machlenkin, and M. Lotem. 2013. Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells. J. Immunol. 190: 5856-5865.
49. Flammiger, A., F. Bayer, A. Cirugeda-Kühnert, H. Huland, P. Tennstedt,R. Simon, S. Minner, C. Bokemeyer, G. Sauter, T. Schlomm, and M. Trepel. 2012. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS 120: 901-908.
50. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102: 18538-18543.